Maternal Opioid Use Disorder: Placental Transcriptome Analysis for Neonatal Opioid Withdrawal Syndrome

Authors

Uppala Radhakrishna, Beaumont Health
Swapan K Nath
Sangeetha Vishweswaraiah, Beaumont Health
Lavanya V Uppala
Ariadna Forray
Srinivas B Muvvala
Ray O Bahado-Singh, Beaumont Health

Document Type

Article

Publication Date

11-2021

Publication Title

Genomics

Abstract

Excessive prenatal opioid exposure may lead to the development of Neonatal Opioid Withdrawal Syndrome (NOWS). RNA-seq was done on 64 formalin-fixed paraffin-embedded placental tissue samples from 32 mothers with opioid use disorder, with newborns with NOWS that required treatment, and 32 prenatally unexposed controls. We identified 93 differentially expressed genes in the placentas of infants with NOWS compared to unexposed controls. There were 4 up- and 89 downregulated genes. Among these, 7 genes CYP1A1, APOB, RPH3A, NRXN1, LINC01206, AL157396.1, UNC80 achieved an FDR p-value of

Volume

113

Issue

6

First Page

3610

Last Page

3617

Recommended Citation

Radhakrishna U, Nath SK, Vishweswaraiah S, Uppala LV, Forray A, Muvvala SB, Mishra NK, Southekal S, Guda C, Govindamangalam H, Vargas D, Gardella WG, Crist RC, Berrettini WH, Metpally RP, Bahado-Singh RO. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome. Genomics. 2021 Nov;113(6):3610-3617. doi: 10.1016/j.ygeno.2021.08.001. Epub 2021 Aug 3. PMID: 34352367.

DOI

doi: 10.1016/j.ygeno.2021.08.001

ISSN

1089-8646

PubMed ID

34352367